A biomimetic hydrogel designed to repair hearts after a myocardial infarction has attracted $16K in new capital for Amnova Biotech. The company is developing a next-generation regenerative therapy that aims to significantly reduce cardiac damage and improve heart function.
Amnova's innovative approach, inspired by birth tissues, focuses on the sustained delivery of recombinant regenerative factors. Crucially, the therapy is designed to operate without cells or animal-derived components, offering a distinct path in cardiac regeneration.
